| Ytd | 338.21% | |
| 1y | 415.39% |
| Open | 139.34 | Prev Close | 141.38 | Low | 135.00 | High | 140.58 | Mkt Cap | 8.72B |
| Vol | 1.89M | Avg Vol | 1.79M | EPS | -2.23 | P/E | N/A | Forward P/E | -219.47 |
| Beta | 2.16 | Short Ratio | 9.36 | Inst. Own | 118.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 106.72 | 200-d Avg | 62.21 | 1yr Est | 105.30 |
Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: T
Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefine
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from curren
Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an ind
TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven prot
Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g
On August 07, 2026, Twist Bioscience Corp (TWST) shares rose by 6.0%, bringing the current price to
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price shot up 10.3% during mid
Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight
Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism abou
Twist Bioscience Corporation (Nasdaq: TWST) (âTwistâ), a mid-cap growth and value biotech compan
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”),
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”),
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, T
Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and rai
First Trust Advisors LP acquired a new position in Twist Bioscience Corporation (NASDAQ: TWST) in th
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal
Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discov
Twist Bioscience NASDAQ: TWST reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% f
Twist Bioscience (TWST) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus
[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company
Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to
Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 millio
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap
Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience Cor
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and rai
Evercore ISI Group analyst Vijay Kumar downgrades Twist Bioscience (NASDAQ:TWST) from Outperform
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
https://www.sec.gov/Archives/edgar/data/1581280/000110465926075726/tm2617605-1_s3asr.htm
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a
Piper Sandler analyst David Westenberg initiates coverage on Twist Bioscience (NASDAQ:TWST) with
-LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform,
Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.
Top analysts change outlooks on top names: UBS raises price target for TD Synnex, BMO Capital raises
Leerink Partners analyst Puneet Souda upgrades Twist Bioscience (NASDAQ:TWST) from Market Perform
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais
Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the
Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and rai
Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.59) per share which missed the analy
Twist Bioscience (NASDAQ:TWST) sees Q3 sales of $114.000 million-$115.000 million vs $111.371 millio
Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of ap
Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $435.000 million-$440.000 million to